Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study

Jiaqiang Wang,1 Shilei Gao,1 Yonghao Yang,2 Xu Liu,1 Peng Zhang,1 Shuping Dong,1 Xin Wang,1 Weitao Yao1 1Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan Province, 450008, People’s Republic of China; 2Department of Immunoth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang J, Gao S, Yang Y, Liu X, Zhang P, Dong S, Wang X, Yao W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	clear cell sarcoma apatinib camrelizumab sarcoma tyrosine kinase inhibitor pd-1 inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/371845295c384a83b738d539131a0ad8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:371845295c384a83b738d539131a0ad8
record_format	dspace
spelling	oai:doaj.org-article:371845295c384a83b738d539131a0ad82021-12-05T18:27:45ZClinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study1179-1322https://doaj.org/article/371845295c384a83b738d539131a0ad82021-12-01T00:00:00Zhttps://www.dovepress.com/clinical-experience-with-apatinib-and-camrelizumab-in-advance-clear-ce-peer-reviewed-fulltext-article-CMARhttps://doaj.org/toc/1179-1322Jiaqiang Wang,1 Shilei Gao,1 Yonghao Yang,2 Xu Liu,1 Peng Zhang,1 Shuping Dong,1 Xin Wang,1 Weitao Yao1 1Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan Province, 450008, People’s Republic of China; 2Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan Province, 450008, People’s Republic of ChinaCorrespondence: Jiaqiang WangDepartment of Orthopaedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan Province, 450008, People’s Republic of ChinaTel +86-18737187831Fax +86-371-65961505Email doctorwangjiaqiang@126.comPurpose: Advanced clear cell sarcoma (CCS) is a rare subtype of sarcoma with few effective treatments. Evidence shows that apatinib is efficacious and safe for CCS. This study aimed to assess the safety and efficacy of apatinib and/or camrelizumab (a PD-1 inhibitor) in treating advanced CCS.Methods: We retrospectively reviewed 12 patients with advanced CCS who received apatinib and/or camrelizumab therapy between November 2018 and July 2021. Standard descriptive statistics were employed for continuous variables and categorical variables (number and percentage).Results: Of the 12 CCS patients, 3 had a partial response (PR), and 4 had stable disease (SD). Among the 5 patients treated with apatinib monotherapy, 1 PR and 2 SD were found, and the addition or replacement of camrelizumab after progressive disease (PD) did not work. In the 4 patients who received apatinib plus camrelizumab combination therapy, 1 PR and 1 SD were found. All 3 patients who received camrelizumab first had PD, and 1 PR and 1 SD were found after adding apatinib. Grade 3 or 4 adverse events were significantly more common in the apatinib plus camrelizumab combination therapy than in the apatinib or camrelizumab monotherapy, and these included increased aspartate aminotransferase and increased alanine aminotransferase levels.Conclusion: Apatinib has promising effectiveness for CCS. Camrelizumab efficacy for the treatment of clear cell sarcoma is inconclusive. The efficacy of apatinib and PD-1 inhibitors in CCS need to be further investigated in prospective clinical trials.Keywords: clear cell sarcoma, apatinib, camrelizumab, sarcoma, tyrosine kinase inhibitor, PD-1 inhibitorWang JGao SYang YLiu XZhang PDong SWang XYao WDove Medical Pressarticleclear cell sarcomaapatinibcamrelizumabsarcomatyrosine kinase inhibitorpd-1 inhibitorNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Management and Research, Vol Volume 13, Pp 8999-9005 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	clear cell sarcoma apatinib camrelizumab sarcoma tyrosine kinase inhibitor pd-1 inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	clear cell sarcoma apatinib camrelizumab sarcoma tyrosine kinase inhibitor pd-1 inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Wang J Gao S Yang Y Liu X Zhang P Dong S Wang X Yao W Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
description	Jiaqiang Wang,1 Shilei Gao,1 Yonghao Yang,2 Xu Liu,1 Peng Zhang,1 Shuping Dong,1 Xin Wang,1 Weitao Yao1 1Department of Orthopedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan Province, 450008, People’s Republic of China; 2Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan Province, 450008, People’s Republic of ChinaCorrespondence: Jiaqiang WangDepartment of Orthopaedics, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan Province, 450008, People’s Republic of ChinaTel +86-18737187831Fax +86-371-65961505Email doctorwangjiaqiang@126.comPurpose: Advanced clear cell sarcoma (CCS) is a rare subtype of sarcoma with few effective treatments. Evidence shows that apatinib is efficacious and safe for CCS. This study aimed to assess the safety and efficacy of apatinib and/or camrelizumab (a PD-1 inhibitor) in treating advanced CCS.Methods: We retrospectively reviewed 12 patients with advanced CCS who received apatinib and/or camrelizumab therapy between November 2018 and July 2021. Standard descriptive statistics were employed for continuous variables and categorical variables (number and percentage).Results: Of the 12 CCS patients, 3 had a partial response (PR), and 4 had stable disease (SD). Among the 5 patients treated with apatinib monotherapy, 1 PR and 2 SD were found, and the addition or replacement of camrelizumab after progressive disease (PD) did not work. In the 4 patients who received apatinib plus camrelizumab combination therapy, 1 PR and 1 SD were found. All 3 patients who received camrelizumab first had PD, and 1 PR and 1 SD were found after adding apatinib. Grade 3 or 4 adverse events were significantly more common in the apatinib plus camrelizumab combination therapy than in the apatinib or camrelizumab monotherapy, and these included increased aspartate aminotransferase and increased alanine aminotransferase levels.Conclusion: Apatinib has promising effectiveness for CCS. Camrelizumab efficacy for the treatment of clear cell sarcoma is inconclusive. The efficacy of apatinib and PD-1 inhibitors in CCS need to be further investigated in prospective clinical trials.Keywords: clear cell sarcoma, apatinib, camrelizumab, sarcoma, tyrosine kinase inhibitor, PD-1 inhibitor
format	article
author	Wang J Gao S Yang Y Liu X Zhang P Dong S Wang X Yao W
author_facet	Wang J Gao S Yang Y Liu X Zhang P Dong S Wang X Yao W
author_sort	Wang J
title	Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
title_short	Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
title_full	Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
title_fullStr	Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
title_full_unstemmed	Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
title_sort	clinical experience with apatinib and camrelizumab in advance clear cell sarcoma: a retrospective study
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/371845295c384a83b738d539131a0ad8
work_keys_str_mv	AT wangj clinicalexperiencewithapatinibandcamrelizumabinadvanceclearcellsarcomaaretrospectivestudy AT gaos clinicalexperiencewithapatinibandcamrelizumabinadvanceclearcellsarcomaaretrospectivestudy AT yangy clinicalexperiencewithapatinibandcamrelizumabinadvanceclearcellsarcomaaretrospectivestudy AT liux clinicalexperiencewithapatinibandcamrelizumabinadvanceclearcellsarcomaaretrospectivestudy AT zhangp clinicalexperiencewithapatinibandcamrelizumabinadvanceclearcellsarcomaaretrospectivestudy AT dongs clinicalexperiencewithapatinibandcamrelizumabinadvanceclearcellsarcomaaretrospectivestudy AT wangx clinicalexperiencewithapatinibandcamrelizumabinadvanceclearcellsarcomaaretrospectivestudy AT yaow clinicalexperiencewithapatinibandcamrelizumabinadvanceclearcellsarcomaaretrospectivestudy
_version_	1718371111264059392

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study

Ejemplares similares